Global, regional, and national burdens of hip osteoarthritis from 1990 to 2019: estimates from the 2019 Global Burden of Disease Study

Ming Fu, Hongming Zhou, Yushi Li, Hai Jin, Xiqing Liu, Ming Fu, Hongming Zhou, Yushi Li, Hai Jin, Xiqing Liu

Abstract

Background: Hip osteoarthritis is a common disabling condition of the hip joint and is associated with a substantial health burden. We assessed the epidemiological patterns of hip osteoarthritis from 1990 to 2019 by sex, age, and socio-demographic index (SDI).

Methods: Age-standardized rates (ASRs) were obtained for the incidence and disability-adjusted life years (DALYs) of hip osteoarthritis from 1990 to 2019 for 21 regions, encompassing a total of 204 countries and territories. The estimated annual percentage changes (EAPCs) of ASRs were calculated to evaluate the trends in the incidence and DALYs of hip osteoarthritis over these 30 years.

Results: Globally, from 1990 to 2019, the age-standardized incidence rate (ASIR) of hip osteoarthritis increased from 17.02 per 100,000 persons to 18.70 per 100,000 persons, with an upward trend in the EAPC of 0.32 (0.29-0.34), whereas the age-standardized DALY rate increased from 11.54 per 100,000 persons to 12.57 per 100,000 persons, with an EAPC of 0.29 (0.27-0.32). In 2019, the EAPCs of the ASIR and age-standardized DALY rate of hip osteoarthritis were positively associated with the SDI of hip osteoarthritis. In 1990 and 2019, the incidence of hip osteoarthritis was unimodally distributed across different age groups, with a peak incidence in the 60-64-year-old age group, whereas the DALYs increased with age.

Conclusions: The incidence and DALYs of hip osteoarthritis have been increasing globally. The EAPCs of the ASIR and age-standardized DALY rate were particularly significant in developed regions and varied across nations and regions, indicating the urgent need for governments and medical institutions to increase the awareness regarding risk factors, consequences of hip osteoarthritis.

Keywords: Age-standardized rates; Disability-adjusted life years; Hip osteoarthritis; Incidence.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
The global ASIR and age-standardized DALY rate (per 100,000) of hip osteoarthritis in 204 countries. A The ASIR of hip osteoarthritis in 2019. B The EAPC of hip osteoarthritis ASIR from 1990 to 2019. C The age-standardized DALY rate of hip osteoarthritis in 2019. D The EAPC of hip osteoarthritis age-standardized DALY rate from 1990 to 2019. Countries with an extreme number of cases/evolution were annotated. ASIR, age-standardized incidence rate; EAPC, estimated annual percentage change. DALY, disability-adjusted life years
Fig. 2
Fig. 2
The change trends of age standardized rate among different SDI quintiles and gender from 1990 to 2019. A ASIR. B Age-standardized DALY rate. ASIR, age-standardized incidence rate; DALY, disability-adjusted life year
Fig. 3
Fig. 3
The EAPC of hip osteoarthritis ASIR and age-standardized DALY rate from 1990 to 2019, by region. A The EAPC of ASIR. B The EAPC of age-standardized DALY rate. ASIR: age standardized incidence rate; EAPC, estimated annual percentage change; DALY, disability-adjusted life year
Fig. 4
Fig. 4
The correlation between EAPC and hip osteoarthritis ASR in 1990 as well as SDI in 2019. A EAPC of ASIR and SDI in 2019. B EAPC of ASIR and ASIR in 1990. C EAPC of age-standardized DALY rate and SDI in 2019. D EAPC of age-standardized DALY rate and age-standardized DALY rate in 1990; The smooth curve was fitted by Loess regression. The circles represent countries that were available on SDI data. The size of circle is increased with the cases of hip osteoarthritis. The ρ indices and P values presented were derived from Pearson correlation analysis. ASIR, age standardized incidence rate; EAPC, estimated annual percentage change; SDI, socio-demographic index; DALY, disability-adjusted life year
Fig. 5
Fig. 5
The incidence and DALY rate of hip osteoarthritis among gender and age. A Incidence rate in 1990. B Incidence rate in 2019. C DALY rate in 1990. D DALY rate in 2019; DALY, disability-adjusted life year

References

    1. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-1759.
    1. Evans J, Evans J, Walker R, Blom A, Whitehouse M, Sayers A. How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up. Lancet. 2019;393(10172):647–654. doi: 10.1016/S0140-6736(18)31665-9.
    1. Aresti N, Kassam J, Nicholas N, Achan P. Hip osteoarthritis. BMJ. 2016;354:i3405. doi: 10.1136/bmj.i3405.
    1. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323–1330. doi: 10.1136/annrheumdis-2013-204763.
    1. Safiri S, Kolahi A, Smith E, Hill C, Bettampadi D, Mansournia M, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79(6):819–828. doi: 10.1136/annrheumdis-2019-216515.
    1. Safiri S, Kolahi A, Cross M, Hill C, Smith E, Carson-Chahhoud K, et al. Prevalence, deaths and disability adjusted life years (DALYs) due to musculoskeletal disorders for 195 countries and territories 1990-2017. Arthritis & Rheumatology (Hoboken, NJ). 2020.
    1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22.
    1. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16:494–502. doi: 10.1136/ard.16.4.494.
    1. Taruc-Uy R, Lynch S. Diagnosis and treatment of osteoarthritis. Primary care. 2013;40(4):821–836. doi: 10.1016/j.pop.2013.08.003.
    1. GBD 2019 Diseases and Injuries Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71.
    1. Deng Y, Wang M, Zhou L, Zheng Y, Li N, Tian T, et al. Global burden of larynx cancer, 1990-2017: estimates from the global burden of disease 2017 study. Aging. 2020;12(3):2545–2583. doi: 10.18632/aging.102762.
    1. Usenbo A, Kramer V, Young T, Musekiwa A. Prevalence of arthritis in Africa: a systematic review and meta-analysis. PLoS One. 2015;10(8):e0133858. doi: 10.1371/journal.pone.0133858.
    1. Abramoff B, Caldera F. Osteoarthritis: pathology, diagnosis, and treatment options. Med Clin North Am. 2020;104(2):293–311. doi: 10.1016/j.mcna.2019.10.007.
    1. Bennell K. Physiotherapy management of hip osteoarthritis. J Physiother. 2013;59(3):145–157. doi: 10.1016/S1836-9553(13)70179-6.
    1. Fransen M, McConnell S, Hernandez-Molina G, Reichenbach S. Exercise for osteoarthritis of the hip. Cochrane Database Syst Rev. 2014;4:CD007912.
    1. Kongsted A, Kent P, Quicke J, Skou S, Hill J. Risk-stratified and stepped models of care for back pain and osteoarthritis: are we heading towards a common model? Pain Rep. 2020;5(5):e843. doi: 10.1097/PR9.0000000000000843.
    1. Saberi Hosnijeh F, Kavousi M, Boer C, Uitterlinden A, Hofman A, Reijman M, et al. Development of a prediction model for future risk of radiographic hip osteoarthritis. Osteoarthr Cartil. 2018;26(4):540–546. doi: 10.1016/j.joca.2018.01.015.
    1. Agricola R, Waarsing JH, Arden NK, et al. Cam impingement of the hip: a risk factor for hip osteoarthritis. Nat Rev Rheumatol. 2013;9:630–634. doi: 10.1038/nrrheum.2013.114.
    1. Harris EC, Coggon D. HIP osteoarthritis and work. Best Pract Res Clin Rheumatol. 2015;29:462–482. doi: 10.1016/j.berh.2015.04.015.
    1. Luong M, Cleveland R, Nyrop K, Callahan L. Social determinants and osteoarthritis outcomes. Aging Health. 2012;8(4):413–437. doi: 10.2217/ahe.12.43.
    1. Sacitharan P. Ageing and osteoarthritis. Sub-Cellular Biochemistry. 2019;91:123–159. doi: 10.1007/978-981-13-3681-2_6.
    1. Hunter D, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020;396(10264):1711–1712. doi: 10.1016/S0140-6736(20)32230-3.
    1. Deng Y, Li H, Wang M, Li N, Tian T, Wu Y, et al. Global burden of thyroid cancer from 1990 to 2017. JAMA Network Open. 2020;3(6):e208759. doi: 10.1001/jamanetworkopen.2020.8759.
    1. Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, et al. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study. J Hematol Oncol. 2019;12(1):107. doi: 10.1186/s13045-019-0799-1.
    1. Glyn-Jones S, Palmer A, Agricola R, Price A, Vincent T, Weinans H, et al. Osteoarthritis. Lancet. 2015;386(9991):376-387.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi